Photo via NBC News

RFK Jr. takes shortcut to make some peptides more widely available

Read the original at NBC News ↗
Cite

Jr., B. L. (2026, October 28). RFK Jr. takes shortcut to make some peptides more widely available. NBC News. https://www.nbcnews.com/health/health-news/rfk-jr-takes-shortcut-make-peptides-widely-available-rcna606133

Dated from the outlet's own feed. Check the original for its byline.

NBC News · collected 2026-10-28 · by Berkeley Lovelace Jr.

Quick Summary

The Department of Health and Human Services has temporarily allowed compounding pharmacies to manufacture six unapproved peptides without legal repercussions while the FDA formalizes new rules for their production. These peptides include BPC-157, epitalon, KPV, MOTS-c, semax, and TB-500, which are marketed as treatments for various health conditions but lack FDA approval due to insufficient safety and efficacy data. The move aims to shift consumers from the current "gray market" of peptides labeled as research-only products towards regulated compounding pharmacies, though critics argue this undermines drug regulation standards.
Written by AI on 2026-10-29, from this article's own text only (the story summary below draws on all the coverage).
See how they differ ↓

AI analysis

Story summary

As of October 28, 2026, the Trump administration's Department of Health and Human Services (HHS) allowed pharmacies to produce and sell six unapproved peptide drugs without FDA approval. This decision faced significant opposition from most FDA scientific staff members who warned it could undermine public health by exposing Americans to potentially unsafe substances. HHS stated that this move is intended to provide a regulated alternative for consumers seeking peptides, which have previously been available through the "gray market," often imported illegally from countries like China. The policy will be in effect while HHS works on formalizing a rule change and is set to take comments for two weeks before finalization.

Written for “RFK Jr Eases Access To Unapproved Peptides” on 2026-11-21, grounded in this article and the 13 other(s) covering the same event.

How they differ

11 outlets covered “RFK Jr Eases Access To Unapproved Peptides”.

What each outlet says

One AI summary per outlet of its latest article on this story, written from that article alone and checked against it. Open the article for the outlet's own words.

NBC NewsThis outlet28 Oct

The Department of Health and Human Services has temporarily allowed compounding pharmacies to manufacture six unapproved peptides without legal repercussions while the FDA formalizes new rules for their production. These peptides include BPC-157, epitalon, KPV, MOTS-c, semax, and TB-500, which are marketed as treatments for various health conditions but lack FDA approval due to insufficient safety and efficacy data…

RFK Jr. takes shortcut to make some peptides more widely available (this article)
CBS News29 Oct

Adam Yamaguchi reports on Robert F. Kennedy Jr.’s efforts to encourage pharmacies to manufacture peptides that have not been approved by the FDA. The article focuses specifically on RFK Jr.’s advocacy for these unregulated substances, which are being promoted despite lacking official approval from regulatory authorities.

Inside RFK Jr.'s push for pharmacies to make non-FDA approved peptides →3 articles from CBS News on this story
ABC News (US)29 Oct

HHS announced that some wellness peptides will be available by prescription. The department will temporarily allow compounding pharmacies to provide six specific peptides through prescriptions. This announcement was made on October 29, 2026.

WATCH: HHS says some wellness peptides will be available by prescription →2 articles from ABC News (US) on this story
Toronto Star28 Oct

FDA scientific staff largely opposed a Trump administration plan aimed at easing access to unproven peptide drugs, despite pushback from Health Secretary Robert F. Kennedy Jr. This policy would allow specialty pharmacies to sell peptides without the FDA's rigorous safety and effectiveness review process, which are currently considered illegal drugs. Most FDA drug staffers warned that this could undermine the…

FDA scientists opposed the Trump administration's move to ease peptides access →
The Guardian28 Oct

FDA scientific staff members opposed a Trump administration plan pushed by Health Secretary Robert F Kennedy Jr, which aimed to ease access to unproven peptide drugs in the US wellness industry. The policy, posted online by HHS on Wednesday, would allow specialty pharmacies to sell several peptides without FDA approval, despite warnings from FDA scientists about potential safety risks. This move faces significant…

FDA scientists opposed Trump administration’s move to ease peptide access →
Time28 Oct

The U.S. Department of Health and Human Services announced on October 28 that it will not take enforcement action against licensed pharmacists who dispense six unapproved peptides to consumers. These peptides include BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500, which are short chains of amino acids injected for various health benefits, despite scientific uncertainty about their safety and efficacy. The policy…

The Peptide Rush Has Begun →
Show 5 more outlets
NPR29 Oct

The Trump administration's Department of Health and Human Services plans to relax restrictions on six unproven peptides, allowing small compounding pharmacies to produce them despite lacking FDA approval. This policy change supports wellness influencers and some clinicians who promote these peptides for various health issues like ulcerative colitis and insomnia, though evidence of their safety and effectiveness is…

Trump administration will allow pharmacies to make popular peptides →
The Independent29 Oct

Health Secretary Robert F. Kennedy Jr. announced a new policy allowing the widespread use of six unapproved peptide compounds, despite the FDA advising against their use due to potential risks. The Health and Human Services Department will not take enforcement action against those selling these peptides, arguing that easing access will provide patients with controlled alternatives while protecting safety through…

RFK Jr says he will allow widespread unapproved injections despite his FDA advising people not to use them →
BBC29 Oct

US Health Secretary Robert F Kennedy Jr has announced plans to relax restrictions on six unapproved peptides through compounding pharmacies, despite warnings from health experts about their potential risks due to insufficient human clinical trials and unknown long-term side effects. The draft regulation was published in the US Federal Register and will undergo a public comment period following its official…

US Health Secretary RFK Jr to expand access to unapproved peptides →
Reason29 Oct

HHS has established a new policy allowing pharmacies to produce and sell six specific peptides without FDA approval, aiming to provide a safer alternative to purchasing these substances from unregulated foreign sources. The decision is seen as a victory for peptide advocates and reflects frustration with FDA's slow processes, despite the lack of formal FDA endorsement or safety reviews for compounded drugs.

RFK Jr. Institutes Backdoor Approval of 6 Peptides →
New York Post29 Oct

The Trump administration recently relaxed regulations to allow easier access to unproven peptide drugs favored by Health Secretary Robert F. Kennedy Jr., despite opposition from the FDA’s scientific staff. The Department of Health and Human Services draft policy targets specific peptides used for wellness purposes such as muscle building and injury healing, allowing specialty pharmacies to sell them without facing…

Trump admin eases access to unproven peptides favored by RFK Jr. despite FDA opposition →

Where they agree and split

Framing

How the first headlines put it

Attributed to a source2
Stated as fact7
The headlines (9)

Some wellness peptides will become widely available, HHS says ABC News · attributed to a source

RFK Jr says he will allow widespread unapproved injections despite his FDA advising people not to use them The Independent · attributed to a source

RFK Jr. takes shortcut to make some peptides more widely available NBC News · stated as fact

FDA scientists opposed the Trump administration's move to ease peptides access Toronto Star · stated as fact

FDA scientists opposed Trump administration’s move to ease peptide access The Guardian · stated as fact

The Peptide Rush Has Begun Time · stated as fact

Trump administration will allow pharmacies to make popular peptides NPR · stated as fact

Dr. Jon LaPook explains why peptide sales are controversial CBS News · stated as fact

US Health Secretary RFK Jr to expand access to unapproved peptides BBC · stated as fact

The full story: what happened, how it changed, and all 14 articles →

Compared with similar articles

This article reads unscored and hedges 21% of its claims. Each row says how that neighbour differs.
NPR
Leans right Hedges 4 of 30 claims Outlet record 60/100
ABC News (US)
Hedges 2 of 14 claims Outlet record 66/100
BBC News
Leans right Hedges 1 of 20 claims Outlet record 65/100
ABC News (US)
Hedges 0 of 1 claims Outlet record 66/100
Reason
Hedges 5 of 23 claims Outlet record 67/100
Toronto Star
Leans left Hedges 5 of 33 claims Outlet record 64/100
The Guardian
Leans left Hedges 4 of 30 claims Outlet record 64/100
TIME
Hedges 3 of 28 claims Outlet record 60/100
The Independent
Hedges 1 of 12 claims Outlet record 59/100
CBS News
Hedges 3 of 22 claims Outlet record 66/100

Story

RFK Jr Eases Access To Unapproved Peptides
Politics · 14 article(s) covering the same event. Compare every outlet's account →
How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted
19
sentences that state something as happening or true
Uncertain
21%
4 of 19 hedged ("reportedly", "may", "according to")
Leaning
withheld
no quote in the article backed the model's score
Publisher signals
77/100
NBC News's corrections and hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
14
Politics
Same framing elsewhere
1
articles that frame the event the way this one does
Analyzed 2026-10-29 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability
Source leaning vs. consistency

Publisher

NBC News · 2728 article(s) · 5 correction(s) detected
Running correction rate · 5 correction(s)

Who wrote this

Berkeley Lovelace Jr.
11 article(s) here · 1 carrying a prediction
Women can also opt for a self-administered HPV test, a major change from the U.S. Preventive Services Task Force that could affect how millions of women are screened for cervical cancer.
Previous research has found that GLP-1 use may increase the risk of NAION, and Lilly has said it was aware of studies on the potential link.
Democrats’ victories in the midterm elections could have a major impact on Americans’ healthcare, from how much people pay for health insurance and prescription drugs to what coverage is available to them, according to health policy experts and former White House advisers.
“Who knows who will cover me in 2027 or how much more it’ll cost,” Mroch said.
In a notice filed Wednesday, the agency said it would exercise “enforcement discretion,” meaning it will not take legal action against compounding pharmacies that make the six unapproved peptides.
Researchers focused on those drugs because patients don’t have the option of switching to cheaper versions, meaning the discounts offered through TrumpRx could have a greater impact on what they pay.
She added, however, that retatrutide “may be too strong for some patients,” particularly those with only mild diabetes or slightly elevated weight.
Dr. Heidi Overton, a fierce opponent of abortion rights, is set to appear before senators Thursday for her confirmation hearing to lead the Food and Drug Administration.
The cuts, Vance said, would save U.S. taxpayers $2.2 billion.
It’s too early to predict how severe the upcoming flu season will be and the Centers for Disease Control and Prevention hasn’t started tracking cases yet.
Also by Berkeley Lovelace Jr.
Nothing else under this byline is closely related to this article, so these are simply their most recent.
All 11 articles by Berkeley Lovelace Jr. →

Topics

FDA HHS The Department of Health and Human Services semax the Food and Drug Administration’s

Subjects

FDA ORG · 9× HHS ORG · 2× Emily Hilliard PERSON · 1× Health ORG · 1× Peter Lurie PERSON · 1× Robert F. Kennedy Jr. PERSON · 1× The Department of Health and Human Services ORG · 1× Trump PERSON · 1× the Center for Science in the Public Interest ORG · 1× the Food and Drug Administration’s ORG · 1×

Narrative

Shabbir Safdar, executive director of the Partnership for Safe Medicines, which researches the dangers of counterfeit medicines, said both the enforcement discretion and upcoming rule change would expose Americans to “untested dangerous substances.”
framing: mixed · carried by 1 article(s) · first seen 2026-10-29
In a notice filed Wednesday, the agency said it would exercise “enforcement discretion,” meaning it will not take legal action against compounding pharmacies that make the six unapproved peptides.

Claims (19 extracted, 4 hedged)

The Department of Health and Human Services is giving compounding pharmacies a temporary green light to make six peptides while the agency continues to work on a formal rule change. asserted
agency → give → change
In a notice filed Wednesday, the agency said it would exercise “enforcement discretion,” meaning it will not take legal action against compounding pharmacies that make the six unapproved peptides. asserted
that → file → peptides
In practice, that means these pharmacies can start offering them now, even though the peptides aren’t yet on the Food and Drug Administration’s list of ingredients compounding pharmacies are allowed to make. asserted
pharmacies → mean → ingredients
They’ve been promoted online as treatments for everything from faster healing to younger-looking skin and a longer lifespan. asserted
They → promote → skin
None are approved by the FDA, and the agency’s own scientists concluded there is insufficient data to prove they are safe and effective. asserted
they → approve → FDA
The FDA said compounding pharmacies must certify the identity and purity of the compounds. asserted
pharmacies → say → compounds
They must also now report side effects, which was not previously mandated. asserted
which → report → effects
The move comes as a growing “gray market” has sprung up around peptides, where retailers sell them labeled “for research use only,” a legal workaround that lets them claim they aren’t meant for humans. uncertain
they → come → humans
Health Secretary Robert F. Kennedy Jr. and others have argued that allowing peptides to be compounded would move people away from this gray market and toward safer products. asserted
peptides → argue → products
“Under President Trump’s leadership, HHS is working to put prevention and patient safety at the center of health care—and that includes confronting the risks of black-market peptides,” Emily Hilliard, an HHS spokesperson, said in a statement. asserted
Hilliard → work → statement
Dr. Peter Lurie, a former FDA official who now leads the Center for Science in the Public Interest watchdog group, said the FDA was essentially “turning a blind eye” to widen access to drugs that have not been proven to work. asserted
that → lead → drugs
Compounding pharmacies generally may use only ingredients the FDA has added to an official list known as the bulk drugs substances list. uncertain
FDA → compound → list
Adding an ingredient requires the FDA to propose a rule, take public comment and issue a final rule, a process that can take several months. asserted
that → add → months
The agency took a step toward that process in July, when an FDA advisory panel narrowly voted in favor of adding six peptides to the bulk list. asserted
panel → take → list
The panel included six new appointees with ties to the peptide industry and another who is the son of a U.S. representative who has pushed Kennedy to make peptides more available. asserted
peptides → include → Kennedy
(During that meeting, some committee members expressed concerns that the recommendation could make it harder for the FDA to say no to other unapproved drugs in the future.) uncertain
FDA → express → future
On Tuesday and Wednesday, the FDA was scheduled to meet outside groups, including Medivant Healthcare, a compounding pharmacy that offers peptides, according to Reginfo.gov, a federal website that tracks government regulations. uncertain
that → schedule → regulations
Shabbir Safdar, executive director of the Partnership for Safe Medicines, which researches the dangers of counterfeit medicines, said both the enforcement discretion and upcoming rule change would expose Americans to “untested dangerous substances.” asserted
discretion → research → substances
“Imagine what it means for the nation’s top drug regulator to announce they won’t enforce the laws on people making completely untested compounds and distributing them to the public,” Safdar said. asserted
Safdar → imagine → public
Give feedback · no sign-in needed

No sign-in needed for now. Your note is sent without a name, so it cannot be answered.

History Support